There’s a lot of buzz about psychedelic drugs and how they will save the world or solve all our problems, but the truth is, there is no way to know for sure if LSD, ecstasy, and psilocybin will take over the world or not. Cannabis, like alcohol and tobacco, isn’t a miracle cure for cancer and other chronic diseases. It’s true that cannabis can be useful in some circumstances for medical conditions, but there is very little evidence to support the idea that cannabis has any effect on the treatment of cancer.
After peaking in late 2017, Bitcoin and Ethereum have been in free-fall, and the rest of the cryptocurrency market has also taken hits. However, Monero, Zcash and other privacy-focused coins have been doing well, with a recent rally that’s led to a doubling of their combined value over the past month.
Psychedelic stocks are fast becoming a hot sector. Do you need proof? Check out Mind Medicine (NASDAQ: MNMD), a promising New York-based biotech startup that specializes in developing addictive psychedelic drugs. The stock just moved from the OTC market to the NASDAQ market and is up over 1,000% in the last nine months. Look at the huge increase in the 12 month chart below. 
I introduced Mind Med to our subscribers in September when I mentioned it in our weekly update. If you would like to receive my email alerts directly to your inbox, sign up for a free two week trial of Cannabis Stock Trades. Mind Med established itself as one of the early pioneers of a larger movement – the birth of psychedelic drug therapy. Researchers are finding increasing evidence that compounds found in psychedelic substances such as LSD, magic mushrooms, MDMA and ketamine have significant medicinal value. This creates a new industry that analysts expect to explode over the next five years. According to leading market research firm Data Bridge, the sector will reach an annual turnover of $6 billion by 2021. The psychedelic drugs market is expected to grow during the forecast period from 2021 to 2028. According to Data Bridge Market Research analysis, the market is growing at a CAGR of 11.5% during the forecast period 2021-2028 and is expected to reach USD 6,433.94 million by 2028. The increasing prevalence of psychiatric depression and anxiety, and the availability of non-oral drugs are the major factors fueling the demand for the psychedelic drugs market during the forecast period. 
If you are looking to invest in the psychedelic therapies sector and have missed out on the mind drugs market, don’t worry. I see the same image unfolding again.
This could be the next big psychedelic action.
A promising psychedelic startup backed by a Facebook billionaire is about to go public. This promising startup:
- It is already one of the largest psychedelic biotechnologies in the world.
- It has already raised $362 million in private equity.
- Cooperates with 14 other companies.
Atai Life Sciences is about to go public. Atai was founded in 2018 and is headquartered in Berlin. The company develops psychedelic drugs to treat mental illnesses such as depression, anxiety and addiction. Here are some details from CNBC. Atai is currently working with 14 companies involved in the development of drugs and other technologies. In exchange for a majority stake in the drugs and technologies they develop, ATAI helps scientists raise funds, collaborate with regulators, and conduct clinical trials. To date, none of the ATAI drugs have been formally approved by regulatory authorities.
3 reasons why Atai is positioned for success
I see three key factors that will give Atai an advantage over the competition.
#1 – Facebook billionaire invests $12 million in Atai
Facebook billionaire Peter Thiel is one of Atai’s biggest investors: last November he invested $12 million in the company. Thiel becomes a taxpayer of psychedelic drugs. Thiel is also a major investor in Compass Pathways (NASDAQ: CMPS), one of the world’s largest psychedelic drug companies, with a market value of $1.3 billion, which went public last fall.
#2 – $362 million already invested
Atai is a well-funded biotech startup. In a recent IPO filing, Atai said it received $362 million in funding from private investors. Atai has diligently used this capital to build an impressive portfolio of biotech companies, partnerships and intellectual property (IP) of psychedelic drugs. This early start in the psychedelic drug market gives Atai a valuable advantage over its competitors.
#3 – Psychedelic Enterprise Fund
Atai is working on a $362 million private equity investment. Atai has already built an impressive portfolio of companies and partnerships developing new treatments. Below is a list of the pharmaceutical product lines of companies that Atai owns or partners with. 
Atai recently applied to join theexchange.
Investors now have the opportunity to own part of Atai. This private company is about to go public. Here are some details from CNBC. ATAI Life Sciences, a biopharmaceutical company specializing in the production of psychedelic drugs to treat mental disorders, has announced plans to raise $100 million in an initial public offering. It plans to sell its shares on the New York technology exchange Nasdaq under the ticker symbol ATAI. The date of the IPO has not yet been determined. This looks like an exciting IPO. Experts predict that the psychedelic drug industry will double in the next five years, and Atai has already emerged as an early leader in this field. I will keep a close eye on Atai for our models portfolio and inform our members when the time comes. You want my next sales alarm? Start your 2 week CST test! Best,Michael Water Editor, Cannabis Effects Trading
About the author and cannabis stock trading
Michael Wodicka is an equity analyst with over 20 years of trading and investment experience. His research has received attention in some of the industry’s most respected publications. He has been investing and managing investors in the cannabis sector since 2013. 
Mr. Vodicka offers his experience and advice to Cannabis Stock Trades members. Sign up for Cannabis Stock Trades and receive exclusive analysis from Mr. Water, trade alerts and a sample portfolio.
Related Tags:
COMPASS Pathways PLC,Champign… Brands Inc.,Cybin,Revive Therapeuti…,Better Plant Sciences,Numinus Wellness,See more,psychedelic stocks on robinhood 2021,undervalued psychedelic stocks,best psychedelic stocks,atai life sciences,psychedelic stocks nasdaq,top 5 psychedelic stocks,list of psychedelic stocks,atai life sciences stock
